Publications
- Targeted treatment with osimertinib in the adjuvant treatment of a patient with non‐small cell lung cancer – case report2023 | Third Faculty of Medicine
- Lung Cancer Versus "Young Cancer": Is Non-Small Cell Lung Cancer in Young Patients a Different Entity?2022 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study2021 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Longer survival in patients with NSCLC thanks to the combination of chemotherapy, immunotherapy and targeted therapy in the first line palliative treatment - results of the IMpower150 study2020 | Third Faculty of Medicine
- Effect of clinical parameters on second- and third-line erlotinib treatment of EGFR wild type patients with advanced NSCLC2019 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University, Second Faculty of Medicine
- EGFR mutations in non-small cell lung cancer - treatment options2019 | Third Faculty of Medicine
- Osimertinib and its use in the treatment of non-small cell lung carcinoma in the Czech Republic2018 | Third Faculty of Medicine
- Extraordinary response to erlotinib therapy in a patient with lung adenocarcinoma exhibiting KRAS mutation and EGFR amplification2011 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Durvalumab in the treatment of locally advanced unresectable non‑small cell lung cancer – case report2023 | First Faculty of Medicine, Third Faculty of Medicine
Loading network view...